HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:
Medivir AB (STO:MVIR), the research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced that safety and efficacy results from the phase IIb PILLAR study of once-daily TMC435 in treatment-naïve patients infected with hepatitis C will be presented as an oral late-breaker at the AASLD meeting in San Francisco, USA today.
Medivir AB (STO:MVIR), the research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced that safety and efficacy results from the phase IIb PILLAR study of once-daily TMC435 in treatment-naïve patients infected with hepatitis C will be presented as an oral late-breaker at the AASLD meeting in San Francisco, USA today.
